低分子肝素钙治疗早期急性脑梗死临床研究  

Low molecular heparin Calcium in early acute cerebral infarction

作　　者：黄杰[1] 郭明艳 杨利君[1] 

机构地区：[1]新乡医学院第二附属医院,河南新乡453002 [2]新乡市医保中心

出　　处：《临床心身疾病杂志》2005年第1期29-30,共2页Journal of Clinical Psychosomatic Diseases

摘　　要：目的　探讨低分子肝素钙治疗早期急性脑梗死的疗效及不良反应。方法　将80例住院患者随机分为观察组40例与 对照组40例。两组均应用低分子右旋糖苷静脉滴注,抵克力得口服,观察组加用低分子肝素钙皮下注射。结果　观察组在用 药后24h、1、2、4w末显效率分别为30.1%、54.2%、80.2%、91.2%,分别高于对照组(24h、1、2w末,P<0.01,4w末P<0 05)。两组不良反应无显著差异。结论　早期急性脑梗死常规治疗联用低分子肝素钙治疗比单纯常规治疗效果显著,安全性 高,值得推广。Objective To explore the curative effect and adverse reactions of low molecular heparins calcium(LMHC) in early acute cerebral infarction. Methods 80 patients were randomly into observing group (n=40,receiving low molecular dextran, ivgtt. and ticlopidine ,Po.) and control group (low molecular dextran , ticlopidine combined with LMHC injection ). Results The effectual rates at the 24th hour and ends of the 1st ,2nd and 4th week after treatment were 30.1%,54.2%,80.2% and 91.2% respectively in the observing group ,which were higher than those of control group (P<0.01~<0.05).There was no significant difference in adverse reactions between the 2 groups .Conclusion Routine treatment combined with LMHC is more efficient and has higher safety.

关 键 词：低分子肝素钙 急性脑梗死 低分子右旋糖苷 抵克力得 

分 类 号：R743.3[医药卫生—神经病学与精神病学]